- An analysis of more than 45,000 people infected with SARS-CoV-2 found a significant association between the virus and the development of persistent high blood pressure among those with no prior history of high blood pressure.
- In addition, people with COVID-19 infection and no history of high blood pressure were significantly more likely to develop persistent high blood pressure compared to people with the influenza virus.
- People with COVID-19 who are over age 40, men, Black adults or those with preexisting conditions, such as chronic obstructive pulmonary disease, coronary artery disease or chronic kidney disease, had an elevated risk of developing high blood pressure, according to the study.
Embargoed until 4 a.m. CT/5 a.m. ET Monday, Aug. 21, 2023
Updated on 8/25/23: addition of "men" in the third bullet of the analysis details, as requested by the research authors.
DALLAS, Aug. 21, 2023 — An analysis of electronic medical records for more than 45,000 people found that COVID-19 infection was significantly associated with the development of high blood pressure, according to new research published today in Hypertension, an American Heart Association journal.
“While COVID-19 is typically more severe in patients with preexisting high blood pressure, including higher rates of hospitalization and mortality compared to people with normal blood pressure, it is unknown whether the SARS-CoV-2 virus may trigger the development of high blood pressure or worsen preexisting hypertension,” said senior study author Tim Q. Duong, Ph.D., professor of radiology and vice chair for radiology research and associate director of Integrative Imaging and Data Science at the Center for Health and Data Innovation at Albert Einstein College of Medicine and Montefiore Health System in New York City.
This retrospective observational study is the first to investigate the development and risk factors associated with persistent high blood pressure in people with COVID-19 infection compared to influenza, a similar respiratory virus. According to the 2017 ACC/AHA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults, hypertension is classified as having top and bottom numbers greater than or equal to 130/80 mm Hg.
Health data were analyzed from electronic medical records at the Montefiore Health System in Bronx, New York, which serves a large, racially and ethnically diverse population. The study included 45,398 people with COVID-19 — hospitalized between March 1, 2020 and February 20, 2022 — and 13,864 people with influenza without COVID-19 — hospitalized between January 2018 and February 20, 2022 — who returned to the hospital system for any medical reasons within an average follow-up period of six months.
The analysis found:
- 21% of people hospitalized with COVID-19 and 11% of those who were not hospitalized for COVID-19 developed high blood pressure, compared to 16% of people hospitalized with influenza and 4% of those not hospitalized for influenza.
- People hospitalized for COVID-19 were more than twice as likely and those not hospitalized are 1.5 times more likely to develop persistent hypertension compared to people hospitalized and non-hospitalized with influenza, respectively.
- People infected with SARS-CoV-2 who were over 40 years old, men, Black adults or those with preexisting conditions, such as chronic obstructive pulmonary disease, coronary artery disease or chronic kidney disease, had an elevated risk of developing high blood pressure.
- Persistent high blood pressure was more common among people infected with SARS-CoV-2 who were treated with vasopressor and corticosteroid medications during the pandemic.
“Given the sheer number of people affected by COVID-19 compared to influenza, these statistics are alarming and suggest that many more patients will likely develop high blood pressure in the future, which may present a major public health burden,” Duong said. “These findings should heighten awareness to screen at-risk patients for hypertension after COVID-19 illness to enable earlier identification and treatment for hypertension-related complications, such as cardiovascular and kidney disease.”
The authors noted that the people in the study were primarily from communities with low socioeconomic status, which may increase their susceptibility to developing high blood pressure after COVID-19 infection. Other factors may also have contributed to the development of high blood pressure in the study patients, including the effects of isolation, psychosocial stress, reduced physical activity, unhealthy diet and weight gain during the COVID-19 pandemic. Researchers also noted that longer follow-up studies will be needed to determine whether the effects of COVID-19-related complications on the heart and blood pressure regulation may resolve on their own, or if there may be long-lasting effects on patients’ cardiovascular systems.
The study’s limitations included that findings were restricted to people who interacted with the health system during the follow-up period and who might be more likely to have severe COVID-19; the possibility that some patients had undiagnosed high blood pressure; the possibility that vaccine status, which might affect severity of COVID-19 illness, may not have been captured in the health care system database if COVID-19 vaccines were administered outside of the system; and the potential for unintended patient selection bias in a retrospective analysis.
- Participants included 45,398 COVID-19 patients hospitalized between March 2020 to August 2022 and 13,864 influenza patients hospitalized between January 2018 to August 2022 without a history of hypertension.
- Health data came from the Montefiore Health System, which includes multiple hospitals located in New York Metropolitan area in the Bronx and surrounding communities that serves a large, diverse patient population, including many patients with lower social economic status. The Bronx and the greater New York City boroughs were an epicenter of SARS-CoV-2 infection early in the pandemic.
- Data was collected upon COVID-19 hospital admission and at follow-up. The follow-up was within 3 and 9 months after COVID-19 or influenza positive test, with the one closest to 6 months taken for both COVID-19 and influenza patients.
Also on 8/25/23: the researchers authors are correcting the limitations listed in the manuscript to align with the limitations listed in the news release.
Co-authors and their disclosures are listed in the manuscript. The study authors reported no outside funding sources for this research.
Statements and conclusions of studies published in the American Heart Association’s scientific journals are solely those of the study authors and do not necessarily reflect the Association’s policy or position. The Association makes no representation or guarantee as to their accuracy or reliability. The Association receives funding primarily from individuals; foundations and corporations (including pharmaceutical, device manufacturers and other companies) also make donations and fund specific Association programs and events. The Association has strict policies to prevent these relationships from influencing the science content. Revenues from pharmaceutical and biotech companies, device manufacturers and health insurance providers and the Association’s overall financial information are available here.
- Available multimedia is on right column of release link. https://newsroom.heart.org/news/covid-19-may-trigger-new-onset-high-blood-pressure?preview=d31108f951dfb6bf04cb91c8825866bd
- After August 21, 2023, view the manuscript online.
- AHA news release: COVID toll realized: CVD deaths take big jump, especially among certain populations (January 2023)
- AHA news release: Heart disease death rates spiked during the COVID-19 pandemic, erasing years of progress (October 2022)
- AHA news release: Heart disease likely to remain #1 killer in U.S. indefinitely due to long-term COVID-19 impact (July 2021)
- Follow AHA/ASA news on X (formerly known as Twitter) @HeartNews
- Follow news from the AHA’s Hypertension journal @HyperAHA
About the American Heart Association
The American Heart Association is a relentless force for a world of longer, healthier lives. We are dedicated to ensuring equitable health in all communities. Through collaboration with numerous organizations, and powered by millions of volunteers, we fund innovative research, advocate for the public’s health and share lifesaving resources. The Dallas-based organization has been a leading source of health information for nearly a century. Connect with us on heart.org, Facebook, X or by calling 1-800-AHA-USA1.
For Media Inquiries and AHA/ASA Expert Perspective: 214-706-1173
John Arnst: John.Arnst@heart.org 214-706-1060
For Public Inquiries: 1-800-AHA-USA1 (242-8721)